Katrin Sjoquist

7PUBLICATIONS
45CO-AUTHORS
Haematological tumoursPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 08, 2026
Olaparib in HR-deficient, metastatic triple-negative breast and platinum-sensitive relapsed ovarian cancers without germline mutations in BRCA1/2: phase 2 EMBRACE trial.

|Jul 06, 2026
Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies.

|Jun 02, 2025
INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner's curse.

Yu Yang Soon, Katrin Sjoquist, Ian C Marschner

|Oct 04, 2024
INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer.

Nick Pavlakis, Kohei Shitara, Katrin Sjoquist

|Oct 31, 2022
Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer.

Katrin M Sjoquist, Andrew Martin, Nick Pavlakis

|Feb 10, 2021
Rapid Resistance of FGFR-driven Gastric Cancers to Regorafenib and Targeted FGFR Inhibitors can be Overcome by Parallel Inhibition of MEK.

David K Lau, Ian Y Luk, Laura J Jenkins

Pageof 2

Frequent Collaborators

3 joint publications

Nick Pavlakis

2 joint publications

R John Simes

2 joint publications

Kohei Shitara

2 joint publications

Martin R Stockler